LG Chem secures FDA clearance for TP53-targeting cancer candidate

LG Chem, a leading South Korean chemical company, has made significant progress in its oncology research by securing clearance from the U.S. Food and Drug Administration (FDA) to proceed with a phase 1/2 clinical trial for its novel anticancer drug candidate, LG00313112. This milestone marks a crucial step forward in the development of a therapy aimed at addressing a specific genetic mutation associated with certain types of cancer.

The drug candidate, LG00313112, was acquired by LG Chem from Frontier Medicines in April of the previous year. It is specifically designed to target the TP53 Y220C mutation, a genetic alteration present in approximately 1 to 3 percent of cancer patients. This mutation leads to structural instability in the p53 protein, which plays a vital role in preventing cancer by inhibiting cell growth and promoting apoptosis. By stabilizing this mutated protein, LG00313112 aims to restore the tumor-suppressing functions of p53, potentially offering a more effective treatment option for patients with such mutations.

One of the notable features of LG00313112 is its first-in-class covalent-binding design, which allows for a stable interaction with the target protein. This mechanism is believed to contribute to the drug's ability to provide a sustained therapeutic effect. Preclinical studies have shown promising results, indicating that the drug can demonstrate efficacy even at low doses and maintain a consistent response in tumor models that also carry co-occurring KRAS mutations. These findings suggest that LG00313112 might be particularly beneficial for patients whose cancers involve multiple genetic alterations.

According to data from the Cancer Genome Atlas, maintained by the U.S. National Cancer Institute, patients with TP53 mutations experience significantly shorter survival periods compared to those without the mutation. On average, these patients survive about 29 months following treatment, which is roughly half the lifespan of patients who do not have the mutation. As of now, there are no commercially available drugs specifically targeting the TP53 Y220C mutation, making LG00313112 a potentially groundbreaking advancement in cancer therapy.

To expedite the global development process, LG Chem has structured the phase 1/2 trial under a unified protocol. The initial phase will focus on evaluating the safety, tolerability, optimal dosage, and early signs of efficacy in patients with advanced solid tumors—specifically those affecting the ovaries, lungs, and breasts—who carry the TP53 Y220C mutation. The subsequent phase will build upon the insights gained from the first part of the trial to further explore the drug’s effectiveness.

Kim Hye-jin, heading LG Chem’s clinical and regulatory affairs department, expressed optimism about the future of LG00313112. She emphasized the importance of identifying patients who may benefit most from the treatment and accelerating the drug’s development to improve outcomes for individuals facing limited treatment options. With this FDA clearance, LG Chem is poised to advance its efforts in developing a new therapeutic approach for a challenging subset of cancer patients.